Role of natriuretic peptides in heart failure patients with special reference to those on cardiac resynchronization therapy

Minerva Cardioangiologica

Volumn 54, Issue 6, 2006, Pages 743-752

  Ricciardi, G ^a   Pieragnoli, P ^a   Colella, A ^a   Giaccardi, M ^a   Padeletti, L ^a   Abbate, R ^a   Gensini, G F ^a   Michelucci, A ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cardiac resynchronization therapy; Heart failure, congestive; Natriuretic peptides

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC PEPTIDE TYPE C; URODILATIN;

CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL FEATURE; EMERGENCY CARE; EMERGENCY WARD; HEART LEFT VENTRICLE FAILURE; HUMAN; NONHUMAN; PRIMARY MEDICAL CARE; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; SYSTOLIC HEART FAILURE;

ARRHYTHMIA; BIOLOGICAL MARKERS; CARDIAC PACING, ARTIFICIAL; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33847328834     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Emdin M, Clerico A, Clemenza F, Galvani M, Latini R, Masson S et al.; Italian Association of Hospital Cardiologists; Italian Society of Cardiology; Italian Federation of Cardiology; Italian Society of Clinical Chemistry and Molecular Biology; Italian Society of Laboratory Medicine; Italian Society of Emergency Medicine. Recommendations for the clinical use of cardiac natriuretic peptides. Ital Heart J 2005;6:430-46.
2. Nozzoli C. B-type natriuretic peptide: where are we? Ann Ital Med Int 2005;20:II-III.
3. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988;332:78-81.
4. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-22.
5. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Due P et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
6. Battaglia M, Pewsner D, Juni P, Egger M, Bucher HC, Bachmann LM. Accuracy of B-type natriuretic peptide tests to exclude congestive heart failure: systematic review of test accuracy studies. Arch Intern Med 2006;166:1073-80.
7. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-54.
8. Wieczorek SJ, Wu AH, Christenson R, Krishnaswamy P, Gottlieb S, Rosano T et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J 2002;144:834-9.
9. Mueller C, Laule-Killian K, Schindler C, Klima T, Frana B, Rodriguez D et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 2006;166:1081-7.
10. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-54.
11. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-HeFT). Circulation 2003;107:1278-83.
12. Christ M, Sharkova J, Bayrakcioglu S, Herzum I, Mueller C, Grimm W. B-type natriuretic peptide level predict event-free survival in patients with implantable cardioverter defibrillators. Eur J Heart Fail 2006 Oct 4; [Epub ahead of print].
13. Verdiani V, Nozzoli C, Bacci F, Cecchin A, Rutili MS, Paladini S et al. Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. Eur J Heart Fail 2005;7:566-71.
14. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 2005;91:606-12.
15. Frantz RP, Olson LJ, Grill D, Moualla SK, Nelson SM, Nobrega TP et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am Heart J 2005;149:541-7.
16. Ben Driss A, Tabet JY, Meurin P, Weber H, Renaud N, Grosdemouge A et al. Role of B-type natriuretic peptide and echocardiographic indices in predicting the development of acute heart failure following beta-blocker uptitration in chronic heart failure patients with left ventricular systolic dysfunction. Int J Cardiol 2006 Jun 10; [Epub ahead of print].
17. Yasumura Y, Miyatake K, Okamoto H, Miyauchi T, Kawana M, Tsutamoto T et al. Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure. Circ J 2004;68:361-6.
18. Carson P, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M et al.; for the I-PRESERVE Investigators. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 2005;1:576-85.
19. Knebel F, Schimke I, Pliet K, Schattke S, Martin S, Borges AC et al. NT-ProBNP in acute heart failure: correlation with invasively measured hemodynamic parameters during recompensation. J Card Fail 2005;11(5 Suppl):S38-41.
20. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-91.
21. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
22. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand heart failure group. J Am Coll Cardiol 2001;37:1781-7.
23. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P et al. Prognostic impact of plasma Nterminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the carvedilol prospective randomized cumulative survival (COPERNICUS) trial. Circulation 2004;110:1780-6.
24. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al.; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235.
25. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M et al.; Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
26. HFSA 2006 Comprehensive Heart Failure Practice Guideline (Heart Failure Society of America) Section 4: Evaluation of Patients for Ventricular Dysfunction and Heart Failure. J Card Fail 2006;12:e16-e25.
27. HFSA 2006 Comprehensive Heart Failure Practice Guideline (Heart Failure Society of America) Section 11: Evaluation and Management of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. J Card Fail 2006;12:e80-e85.
28. Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc Res 2005;69:318-28.
29. McGrath MF, Kuroski de Bold ML, de Bold AJ. The endocrine function of the heart. Trends Endocrinol Metab 2005;16:469-77.
30. Clerico A, Recchia FA, Passino C, Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006;290:H17-29.
31. Bettencourt P. NT-proBNP and BNP: biomarkers for heart failure management. Eur J Heart Fail 2004;6:359-63.
32. McGrath MF, de Bold AJ. Determinants of natriuretic peptide gene expression. Peptides 2005;26:933-43.
33. Soeki T, Kishimoto I, Okumura H, Tokudome T, Horio T, Mori K et al. C-type natriuretic peptide, a novel anti-fibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol 2005;45:608-l6.
34. Mann DL. Mechanisms and models in heart failure. A combinatorial approoach. Circulation 1999;100:999-1008.
35. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215-62.
36. Brilla CG. Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiovasc Res 2000;47:1-3.
37. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz 2000;25:299-306.
38. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-9.
39. Kjaer A, Hesse B. Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. Clin Physiol 2001;21:661-72.
40. Ferrara R, Mastrorilli F, Pasanisi G, Censi S, D'Aiello N, Fucili A et al. Neurohormonal modulation in chronic heart failure. Eur Heart J 2002;4 Suppl D:D3-11.
41. Rothenburger M, Wichter T, Schmid C, Stypmann J, Tjan TD, Berendes E et al. Aminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure. J Heart Lung Transplant 2004;23:1189-97.
42. Moe GW. BNP in the diagnosis and risk stratification of heart failure. Heart Fail Monit 2005;4:116-22.
43. de Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 1996;31:7-18.
44. MacKenna D, Summerour SR, Villarreal FJ. Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc Res 2000;46:257-63.
45. Atance J, Yost MJ, Carver W. Influence of the extracellular matrix on the regulation of cardiac fibroblast behavior by mechanical stretch. J Cell Physiol 2004;200:377-86.
46. de Bold AJ, de Bold ML. Determinants of natriuretic peptide production by the heart: basic and clinical implications. J Investig Med 2005;53:371-7.
47. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32.
48. Vanerheyden M, Goethals M, Verstreken S, De Bruyne B, Muller K, Van Schuerbeeck E et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol 2004;44:2349-54.
49. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002;91:1127-34.
50. Calderone A, Bel-Hadj S, Drapeau J, El-Helou V, Gosselin H, Clement R, Villeneuve L. Scar myofibroblasts of the infarcted rat heart express natriuretic peptides. J Cell Physiol 2006;207:165-73.
51. Bruckner BA, Stetson SJ, Farmer JA, Radovancevic B, Frazier OH, Noon GP et al. The implications for cardiac recovery of left ventricular assist device support on myocardial collagen content. Am J Surg 2000;180:498-501.
52. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:1388-93.
53. Bruckner BA, Stetson SJ, Perez-Verdia A, Youker KA, Radovancevic B, Connelly JH et al. Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support. J Heart Lung Transplant 2001;53:457-64.
54. Shinohara H, Fukuda N, Soeki T, Sakabe K, Onose Y, Tamura Y. Effects of angiotensin II receptor antagonists on [(123)I]metaiodobenzylguanidine myocardial imaging findings and neurohumoral factors in chronic heart failure. Heart Vessels 2002;17:47-52.
55. Kuhn M, Voss M, Mitko D, Stypmann J, Schmid C, Kawaguchi N et al. Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure. Cardiovasc Res 2004;64:308-14.
56. Thompson LO, Skrabal CA, Loebe M, Lafuente JA, Roberts RR, Akgul A et al. Plasma neurohormone levels correlate with left ventricular functional and morphological improvement in LVAD patients. J Surg Res 2005;123:25-32.
57. Conaway DG, Sullivan R, McCullough PA. Improved symptoms, physical limitation, and self-efficacy after resynchronization in a patient with heart failure and a prolonged QRS duration. Rev Cardiovasc Med 2004;5:53-7.
58. Erol-Yilmaz A, Verberne HJ, Schrama TA, Hrudova J, De Winter RJ, Van Eck-Smit BL et al. Cardiac resynchronization induces favorable neurohumoral changes. Pacing Clin Electrophysiol 2005;28:304-10.
59. D'Ascia C, Cittadini A, Monti MG, Riccio G, Sacca L. Effects of biventricular pacing on interstitial remodelling, tumor necrosis factor-{alpha} expression, and apoptotic death in failing human myocardium. Eur Heart J 2005;27:201-6.
60. Braun MU, Rauwolf T, Zerm T, Schulze M, Schnabel A, Strasser RH. Long term biventricular resynchronisation therapy in advanced heart failure: effect on neurohormones. Heart 2005;91:601-5.
61. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L et al.; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49.
62. Theodorakis GN, Flevari P, Kroupis C, Adamopoulos S, Livanis EG, Kostopoulou A et al. Antiinflammatory effects of cardiac resynchronization therapy in patients with chronic heart failure. Pacing Clin Electrophysiol 2006;29:255-61.
63. Lappegard KT, Bjornstad H. Anti-inflammatory effect of cardiac resynchronization therapy. Pacing Clin Electrophysiol 2006;29:753-8.
64. Yu CM, Fung JW, Zhang Q, Chan CK, Chan I, Chan YS et al. Improvement of serum NT-ProBNP predicts improvement in cardiac function and favorable prognosis after cardiac resynchronization therapy for heart failure. J Card Fail 2005;11(5 Suppl):S42-6.
65. Thal SG, Cummings JE, Civello KC, Van Wagoner DR, Saenz LC, Hong M et al. Evidence of inflammatory and hemodynamic remodeling after biventricular device implantation for heart failure. Heart Rhythm 2005;2 Suppl 1:8100.
66. Sinha AM, Breithardt OA, Skobel EC, Filzmaier K, Markus KU, Karla D et al. Long-term effects of cardiac resynchronization therapy on brain natriuretic peptide release and left ventricular function in patients with heart failure. Heart Rhythm 2005;2 Suppl 1:S100-S101.
67. Mortada ME, Bhatia A, Bangash A, Nangia V, Sra J, Blanck Z et al. Effect of biventricular pacing on plasma B-type natriuretic peptide levels in patients with heart failure. Heart Rhythm 2005;2 Suppl 1:S101.
68. Boriani G, Regoli F, Saporito D, Martignani C, Toselli T, Biffi M et al. Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: time courses and prediction of response. Peptides 2006;27:1776-86.
69. Glick A, Michowitz Y, Keren G, George J. Neurohormonal and inflammatory markers as predictors of short-term outcome in patients with heart failure and cardiac resynchronization therapy. Isr Med Assoc J 2006;8:391-5.
70. Pitzalis MV, Iacoviello M, Di Serio F, Romito R, Guida P, De Tommasi E et al. Prognostic value of brain natriuretic peptide in the management of patients receiving cardiac resynchronization therapy. Eur J Heart Fail 2006;8:509-14.
71. Kubanek M, Malek I, Bytesnik J, Fridl P, Riedlbauchova L, Karasova L et al. Decrease in plasma B-type natriuretic peptide early after initiation of cardiac resynchronization therapy predicts clinical improvement at 12 months. Eur J Heart Fail 2006;8:832-40.
72. Filzmaier K, Sinha AM, Breithardt OA, Stiegler H, Fischer Y, Graf J et al. Short-term effect of cardiac resynchronization on brain natriuretic peptide release in patients with systolic heart failure and ventricular conduction disturbance. J Am Coll Cardiol 2002;39:104.
73. Sinha AM, Filzmaier K, Breithardt OA, Kunz D, Graf J, Markus KU et al. Usefulness of brain natriuretic peptide release as a surrogate marker of the efficacy of long-term cardiac resynchronization therapy in patients with heart failure. Am J Cardiol 2003;91:755-8.
74. Molhoek SG, Bax JJ, van Erven L, Bootsma M, Steendijk P, Lentjes E et al. Atrial and brain natriuretic peptides as markers of response to resynchronisation therapy. Heart 2004;90:97-8.
75. Penicka M, Bartunek J, de Bruyne B, Vanderheyden M, Goethals M, De Zutter M et al. Improvement of left ventricular function after cardiac resynchronization therapy is predicted by tissue Doppler imaging echocardiography. Circulation 2004;109:978-83.
76. Hernandez Madrid A, Miguelanez Diaz M, Escobar Cervantes C, Blanco Tirados B, Marin I, Bernal E et al. Usefulness of brain natriuretic peptide to evaluate patients with heart failure treated with cardiac resynchronization. Rev Esp Cardiol 2004;57:299-305.
77. Rubaj A, Rucinski P, Rejdak K, Oleszczak K, Duma D, Grieb P et al. Biventricular versus right ventricular pacing decreases immune activation and augments nitric oxide production in patients with chronic heart failure. Eur J Heart Fail 2006;8:615-20.
78. Civello KC Jr, McWilliams MJ, Chung MK. Usefulness of plasma BNP to determine responders and non-responders of cardiac resynchronization therapy. Heart Rhythm 2005;2 Suppl 1:S101.
79. Ricciardi G, Gori AM, Pappone A, Giaccardi M, Marcucci R, Pieragnoli P et al. NT-pro-BNP identifies patients with high risk of cardiac events in the first six months after cardiac resynchronization therapy. Europace Suppl 2005;7:S31.
80. Delgado RM, Palanichamy N, Radovancevic R, Vrtotec B, Radovancevic B. Brain natriuretic peptide levels and response to cardiac resynchronization therapy in heart failure patients. Congest Heart Fail 2006;12:250-3.
81. Bank AJ, Kelly AS, Burns KV, Adler SW. Cardiac resynchronization therapy: role of patient selection. Curr Cardiol Rep 2006;8:336-42.